Insilico, Pfizer to jointly explore novel data and AI system for potential therapeutic targets

Insilico, Pfizer to jointly explore novel data and AI system for potential therapeutic targets

Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases. Insilico is advancing its latest target identification systems utilizing machine learning, generative biology methods, and synthetic data generation pipelines, and we are pleased to be collaborating with Pfizer on its target identification efforts. Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine We look forward to working with Insilico as Pfizer continues to explore new technologies that may be able to help us identify targets and biomarkers that could assist in our discovery programs, and potentially lead to breakthrough therapeutics for patients with unmet medical needs. Morten Sogaard, Vice President, Target Sciences, Pfizer In September 2019, Insilico Medicine announced a $37 million round led by prominent biotechnology and AI investors. Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More